Amneal’s second quarter results reflected ongoing momentum driven by expanded product launches and strength across its core Affordable Medicines and Specialty segments. However, the market reacted negatively despite the company’s revenue and non-GAAP profit both surpassing Wall Street’s expectations. Management attributed growth to robust demand for transdermal patches in Women’s Health, increased uptake of new complex generics, and the continued success of branded products like CREXONT and BREKIYA. Co-CEO Chirag Patel noted, “The scale of opportunity in front of us today has never been greater,” highlighting recent approvals and pipeline advances as central to performance.
Is now the time to buy AMRX? Find out in our full research report (it’s free for active Edge members).
Amneal (AMRX) Q2 CY2026 Highlights:
- Revenue: $796.2 million vs analyst estimates of $768.2 million (9.9% year-on-year growth, 3.6% beat)
- Adjusted EPS: $0.30 vs analyst estimates of $0.23 (30.3% beat)
- Adjusted EBITDA: $206.5 million vs analyst estimates of $180.6 million (25.9% margin, 14.3% beat)
- The company lifted its revenue guidance for the full year to $3.15 billion at the midpoint from $3.1 billion, a 1.6% increase
- Management slightly raised its full-year Adjusted EPS guidance to $1.01 at the midpoint
- EBITDA guidance for the full year is $765 million at the midpoint, above analyst estimates of $748.8 million
- Operating Margin: 16.3%, in line with the same quarter last year
- Market Capitalization: $5.89 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Amneal’s Q2 Earnings Call
- Glen Santangelo (Barclays) asked about launch timing for key products. Co-CEO Chirag Patel confirmed lanreotide is forecast for Q3 and XOLAIR could launch late in the year, with financial guidance conservatively factoring in these events.
- Ekaterina Knyazkova (JPMorgan) inquired about tariff impacts and CREXONT trends. Patel said Amneal’s U.S. manufacturing footprint helps mitigate tariff risk, and highlighted CREXONT’s broad uptake among general neurologists as a new growth driver.
- David Amsellem (Piper Sandler) questioned the market potential for iohexol and lanreotide. Co-CEO Chintu Patel explained iohexol’s expansion will be staged as new strengths are approved, while lanreotide’s entry barriers and supply control could provide sustained market leadership.
- Ashwani Verma (UBS) asked about FDA process for lanreotide and iohexol adoption. Patel stated FDA review is ongoing with no negative feedback, and that expanding iohexol SKUs will help maximize share, though meaningful revenue is expected from 2027.
- Matthew Dellatorre (Goldman Sachs) sought clarity on major strategic focuses. Chirag Patel pointed to biosimilars integration and GLP-1 partnerships as key, and detailed ongoing investments to scale affordable medicines and specialty brands.
Catalysts in Upcoming Quarters
Looking ahead, our analysts will be watching (1) the successful integration and commercial execution of the Kashiv biosimilars platform, (2) regulatory progress and market uptake for upcoming launches like lanreotide and additional complex generics, and (3) the pace and impact of expanded manufacturing capacity for transdermal patches and injectables. Additionally, the evolution of tariff policy and FDA feedback on key pipeline assets remain important signposts.
Amneal currently trades at $18.84, down from $19.10 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
The Best Stocks for High-Quality Investors
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
